Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BV100 + polymyxin B + ceftazidime + avibactam
- Development stage
- Unknown
- Lead developer
- BioVersys
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
BV100 + polymyxin B + ceftazidime + avibactam is an experimental combination antibiotic regimen developed by BioVersys AG for the treatment of severe infections caused by Carbapenem-resistant Acinetobacter baumannii calcoaceticus complex (CRABC). The regimen centers on BV100, a novel intravenous formulation of rifabutin that targets bacterial RNA polymerase and exhibits active uptake into Gram-negative bacteria. It is combined with low-dose polymyxin B (a membrane-disrupting agent) and ceftazidime/avibactam (a cephalosporin/beta-lactamase inhibitor combination) to provide a synergistic approach against multi-drug resistant pathogens. This combination is primarily being evaluated for hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), bloodstream infections (BSI), and meningitis/ventriculitis.
- Other names
- BV100 in combination with low dose polymyxin B plus ceftazidime/avibactamBV100 + polymyxin B + ceftazidime/avibactam
02
Targets
RNAP (Bacterial dna-dependent RNA polymerase)
Beyond the preview
Go deeper on BV100 + polymyxin B + ceftazidime + avibactam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BV100 + polymyxin B + ceftazidime + avibactam.